BIO Comments on FDA Draft Guidance on Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations
July 19, 2019
BIO submitted comments on the Food and Drug Administration (FDA) Draft Guidance, Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.
BIO welcomes the guidance on using comparative analytical studies to assess whether a proposed therapeutic protein product is biosimilar to a reference product for purposes of submitting a marketing application under section 351(k) of the Public Health Service (PHS) Act. In the comments, BIO provides specific changes to clarify the guidance.
Download Full Comments Below
FINAL BIO Comments Comparative Analytical Assessment And Other Quality-Related Considerations
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
BIO submitted comments on the Food and Drug Administration (FDA) Draft Guidance, Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.
BIO welcomes the guidance on using comparative analytical studies to assess whether a proposed therapeutic protein product is biosimilar to a reference product for purposes of submitting a marketing application under section 351(k) of the Public Health Service (PHS) Act. In the comments, BIO provides specific changes to clarify the guidance.